Ozempic Lowers Kidney Disease Risk by 24% in New Study
TL;DR
Novo Nordisk's diabetes drug Ozempic shows promising results in treating chronic kidney disease (CKD), significantly reducing the risk of major kidney and cardiovascular events in high-risk patients. This development could lead to FDA approval for CKD treatment, expanding Ozempic's market and boosting Novo Nordisk's revenue growth.
Topics:healthbusinesspharmaceuticals#businesspharmaceuticals#chronic-kidney-disease#fda-approval#novo-nordisk#ozempic#semaglutide
- Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again The Motley Fool
- Now, weight loss drug semaglutide can lower risk of kidney disease by 24 per cent The Indian Express
- Ozempic may help fight kidney disease, study with Orlando researcher finds Orlando Sentinel
- #VisualAbstract: Semaglutide Improves Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease 2 Minute Medicine
- Study finds Ozempic cuts risk of chronic kidney disease complications, Epidurals linked to reduction in serious complications after childbirth, Moroccan Fava Bean Soup WPR
Want the full story? Read the original reporting
Read on The Motley Fool